The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious
about
Chemical Variations on the p53 Reactivation ThemeExhaustive Fluorine Scanning toward Potent p53-Mdm2 AntagonistsHalogen-Enriched Fragment Libraries as Leads for Drug Rescue of Mutant p53Transient Protein States in Designing Inhibitors of the MDM2-p53 InteractionStructural basis of how stress-induced MDMX phosphorylation activates p53Probing Difference in Binding Modes of Inhibitors to MDMX by Molecular Dynamics Simulations and Different Free Energy MethodsEnergetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 InteractionMDM2 and MDMX: Alone and together in regulation of p53Organocatalytic, diastereo- and enantioselective synthesis of nonsymmetric cis-stilbene diamines: a platform for the preparation of single-enantiomer cis-imidazolines for protein-protein inhibition.Potential pharmacological chaperones targeting cancer-associated MCL-1 and Parkinson disease-associated α-synuclein.Small-molecule inhibitor starting points learned from protein-protein interaction inhibitor structure.From laptop to benchtop to bedside: structure-based drug design on protein targets.Targeting protein-protein interactions as an anticancer strategySmall-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.Rational design of topographical helix mimics as potent inhibitors of protein-protein interactions.A re-examination of the MDM2/p53 interaction leads to revised design criteria for novel inhibitors.Fragment-based library generation for the discovery of a peptidomimetic p53-Mdm4 inhibitorStructural basis for inhibition of the MDM2:p53 interaction by an optimized MDM2-binding peptide selected with mRNA display.Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach.Interrogation of MDM2 phosphorylation in p53 activation using native chemical ligation: the functional role of Ser17 phosphorylation in MDM2 reexamined.PocketQuery: protein-protein interaction inhibitor starting points from protein-protein interaction structure.Molecular dynamic simulation insights into the normal state and restoration of p53 function.Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal Acute Myeloid Leukemia and Acute Promyelocytic LeukemiaLithocholic acid is an endogenous inhibitor of MDM4 and MDM2.The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastomaMonitoring Ligand-Induced Protein Ordering in Drug Discovery.Benzimidazole-2-one: a novel anchoring principle for antagonizing p53-Mdm2In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of pyrazole-based small molecule inhibitors of Mdm2/4-p53 interaction.The p53-MDM2/MDMX axis - A chemotype perspective.Discovery of highly potent p53-MDM2 antagonists and structural basis for anti-acute myeloid leukemia activities.Mdm2 and MdmX as Regulators of Gene ExpressionMdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present).The clinical development of p53-reactivating drugs in sarcomas - charting future therapeutic approaches and understanding the clinical molecular toxicology of Nutlins.Targeting p53-MDM2-MDMX loop for cancer therapy.2,30-Bis(10H-indole) heterocycles: New p53/MDM2/MDMX antagonists.Identification of antipsychotic drug fluspirilene as a potential p53-MDM2 inhibitor: a combined computational and experimental study.Design of p53-derived peptides with cytotoxicity on breast cancer.Prospective virtual screening for novel p53-MDM2 inhibitors using ultrafast shape recognition.Hot-spot identification on a broad class of proteins and RNA suggest unifying principles of molecular recognition.Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-mannich ring-opening-cyclization reaction mechanism in spiro-oxindoles.
P2860
Q26749008-CA47DFE1-BD60-45D4-A7E9-4EE8CCB9BE06Q27674554-411B959E-D4F0-4ED3-A3D5-7FC6230E54D1Q27678152-E5877CBF-9CFF-4CEF-9721-36BECBF7462EQ27680560-0AC41DBE-6014-4ADD-B6A5-2A9BA548421EQ27701526-F6349C27-BDD2-4867-A3EB-43917A5E3137Q28550543-53E95789-6CF9-4634-82EB-E2F67452AE9AQ28550874-2D0AFECA-EC85-47E4-931A-A15C0BAF8735Q28611422-BC2B7D58-76EA-401F-9E8D-1ACF5DC357C1Q33998827-6BAE0EFC-B326-4021-9FEE-3A304831E683Q34002451-8C70D47D-319D-4135-BFBF-AEB819EDEED0Q34115282-EB56C81D-E41D-4076-BE07-C41710EBCBE0Q34153589-1A27DF5B-8272-4A94-942D-39FE27E64304Q34347892-2D647E8B-6DD7-425B-8890-C68B3F51F548Q35087851-5D3F23A0-A18E-4560-A374-66EEA4EE9377Q35157579-EB92BA16-C0E0-479E-AE08-CE36E684EDC0Q35163150-1B4B0E1B-79C9-42A5-A051-580DE9743A2EQ35199094-6966C7AE-307A-41D8-937C-210F8711734DQ35295410-5A8A00E7-0999-49D4-B9B9-83479A9FBF79Q35411745-CA8E5637-9D6E-4D59-BEE0-2496C7AAA106Q35922756-FF4B3901-AA40-415F-83EA-2FD1F552A08BQ36088526-AF65337F-D0C1-4F43-A583-C90980755279Q36202281-CA9B2636-D417-4878-B8F4-6C379D3DCCA7Q36322508-3B057BB4-A8D1-4554-8778-A53B99FDBD17Q36342520-FC5E568C-23AB-4835-A627-C38977B01FF2Q36692848-9BEDBD9B-CA6C-49F3-A2F9-4CF229BD0553Q36782842-A9F43309-019B-46EF-8196-C38DD5C7725FQ37026970-24A58121-3927-40EA-8EFD-BD40BE3D4A31Q37275707-E1C564C2-38C1-48E0-B1D4-99A226E6A873Q37503463-66664837-CA9E-4BB9-A166-59E94BB39674Q37701743-077C66F1-B9A5-4C9C-8A8F-33852D94BD6EQ38059700-2ACA4D28-1D77-484D-8F35-46A7E1110DEBQ38078456-44B6AFB7-24E8-4E94-B784-D96FF865AF00Q38192005-69F7ABDF-898F-4568-8E0C-45305DB9DF2FQ38247168-E51641C4-4C59-4114-B55E-4DCD2FD93F68Q38603245-6DAF49F6-C18C-4F63-8F5F-EB9D47067847Q38942084-395D76D1-A492-4CF6-975B-9D7F7BE41053Q38994726-E723A157-ABE1-4E06-B2A2-68F62F771C46Q39022371-49DA71E0-EC50-4827-8F10-F46081B8000AQ41512122-D78B0295-5EE5-4D62-A92F-170208656250Q42099865-FD371CB9-8613-4174-ABD8-4520A0F4DD0B
P2860
The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious
@en
The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious.
@nl
type
label
The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious
@en
The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious.
@nl
prefLabel
The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious
@en
The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious.
@nl
P2093
P2860
P356
P1476
The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious
@en
P2093
Alexander Dömling
Grzegorz M Popowicz
Tad A Holak
P2860
P304
P356
10.1002/ANIE.201003863
P407
P577
2011-02-21T00:00:00Z